黛力新辅助治疗难治性胃食管反流病疗效观察

目的:观察黛力新辅助治疗难治性胃食管反流病的临床疗效。方法:90例难治性胃食管反流病患者采取随机双盲分为对照组和观察组,所有患者使用雷贝拉唑肠溶片(10 mg,qd)、莫沙必利分散片(5 mg,tid)及铝碳酸镁片(0.5 tid)治疗4周;观察组加用黛力新(1片,bid)治疗4周。治疗前后观察烧心、反流、焦虑和抑郁等症状,并采用胃食管反流病诊断问卷进行症状积分,比较2组治疗效果。结果:治疗后对照组和观察组的总有效率分别为64.4%、95.6%(P0.05);治疗后2组HAMD及HAMA评分均较治疗前改善,但对照组治疗前、后比较,差异不显著(P0.05),观察组治疗后HAMD及HAMA评分下降程度均明显优于对照组(均P0.05)。结论:黛力新辅助治疗难治性胃食管反流病具有较好的临床疗效。

Observation on the efficacy of Deanxit in auxiliary treatment of refractory gastroesophageal reflux disease

Objective：To observe the efficacy of Deanxit in auxiliary treatment of refractory gastroesophageal reflux disease.Methods：Ninety patients with refractory gastroesophageal reflux disease were double-blindly and randomly divided into observation group and control group.All groups were treated with Rabeprazole sodium enteric-coated tablet （10 mg qd）,Mosapride dispersible tablet （5 mg tid） and Hydrotalcite tablet （0.5 tid） for 4 weeks,and patients in observation group were treated with Deanxit （one tablet,bid） for 4 weeks additionally.The symptoms of heartburn,reflux,depression and anxiety were observed before and after treatments by using the GERD Questionnaire for Hamilton Depression Scale （HAMD） and Hamilton Anxiety Scale （HAMA）,and the therapeutic effect were compared between two groups.Results：The total effective rate of two groups were 64.4% and 95.6%,respectively,and there was significant difference between two groups （P 〈0.05）.The scores of HAMD and HAMA were improved after treatments in two groups,but there was no significant difference in control group before and after treatments （P 〉 0.05）.The scores of HAMD and HAMA decreased significantly in observation group than those of control group after treatments （P 〈 0.05）.Conclusion：Deanxit can be considered as an effective therapeutic method for auxiliary treatment of refractory gastroesophageal reflux disease.